Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 1.07 (8.98%)
Market Cap$468,809,100
Shares Outstanding36,090,000
Data as of 04/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
04/24/14Cytokinetics to Announce First Quarter Results on May 6, 2014Printer Friendly Version
04/23/14Cytokinetics to Host Investor Breakfast and Webcast Following Presentation of Results from BENEFIT-ALSPrinter Friendly Version
04/22/14Cytokinetics Announces Results From BENEFIT-ALS Will Be Presented at the 66th Annual Meeting of the American Academy of NeurologyPrinter Friendly Version
04/01/14Cytokinetics to Present at the 13th Annual Needham Healthcare ConferencePrinter Friendly Version
Upcoming EventsDetails >>
05/06/14 4:30 p.m. ET
Q1 2014 Cytokinetics, Inc. Earnings Conference Call
Featured ReportDetails >>
Download Documentation 2010 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.